Literature DB >> 9743294

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

O Thews1, R Koenig, D K Kelleher, J Kutzner, P Vaupel.   

Abstract

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single non-curative dose (10 Gy), resulting in a growth delay with a subsequent regrowth of the tumours. In the rhEPO-treated group, the growth delay lasted significantly longer (9.5 days vs. 4.5 days) and the regrowth was slower (6.0 days vs. 4.1 days) compared with the anaemic group. These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743294      PMCID: PMC2062974          DOI: 10.1038/bjc.1998.572

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Tumor growth and cell kinetics in chronically hypoxic animals.

Authors:  I F Tannock; G G Steel
Journal:  J Natl Cancer Inst       Date:  1970-07       Impact factor: 13.506

2.  The effect of anaemia on the fraction of hypoxic cells in an experimental tumour.

Authors:  R P Hill; R S Bush; P Yeung
Journal:  Br J Radiol       Date:  1971-04       Impact factor: 3.039

Review 3.  Recombinant human erythropoietin and the anemia of cancer.

Authors:  J L Spivak
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

4.  Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial.

Authors:  S Vijayakumar; M Roach; W Wara; S K Chan; C Ewing; S Rubin; H Sutton; H Halpern; A Awan; A Houghton
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-07-15       Impact factor: 7.038

5.  Erythropoietin increases hemoglobin in cancer patients during radiation therapy.

Authors:  R S Lavey; W H Dempsey
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-12-01       Impact factor: 7.038

6.  Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.

Authors:  E de Campos; J Radford; W Steward; R Milroy; M Dougal; R Swindell; N Testa; N Thatcher
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

7.  Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion.

Authors:  D K Kelleher; U Matthiensen; O Thews; P Vaupel
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

8.  The role of tumor volume in 'reoxygenation' upon cyclophosphamide treatment.

Authors:  M Busse; P W Vaupel
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

9.  The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.

Authors:  M Markman; B Reichman; T Hakes; S Rubin; W Jones; J L Lewis; R Barakat; J Curtin; L Almadrones; W Hoskins
Journal:  Gynecol Oncol       Date:  1993-05       Impact factor: 5.482

10.  The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse.

Authors:  B Joiner; V K Hirst; S R McKeown; J J McAleer; D G Hirst
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more
  24 in total

1.  Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression?

Authors:  Glen Kristiansen; Junmin Hu; Daniela Wichmann; Daniel P Stiehl; Michael Rose; Josefine Gerhardt; Annette Bohnert; Anette ten Haaf; Holger Moch; James Raleigh; Mahesh A Varia; Patrick Subarsky; Francesca M Scandurra; Erich Gnaiger; Eva Gleixner; Anne Bicker; Max Gassmann; Thomas Hankeln; Edgar Dahl; Thomas A Gorr
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

Review 2.  [The aftercare principle for metastasizing prostate cancer. Few diagnostics, much support].

Authors:  K Heine; J M Wolff
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 3.  Impact of anemia in patients with head and neck cancer treated with radiation therapy.

Authors:  Kenneth Hu; Louis B Harrison
Journal:  Curr Treat Options Oncol       Date:  2005-01

4.  Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy.

Authors:  Pilar M Samper Ots; Aurora Rodríguez Pérez; Concepción López Carrizosa; Carmen Vallejo Ocaña; Juan de Dios Sáez Garrido; José M Delgado Pérez
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

Review 5.  Hypoxia and anaemia in patients with cancer of the uterine cervix.

Authors:  Francisco José Andreu-Martínez; Julia M Martínez-Mateu
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

6.  Erythropoietin in cancer treatment: considerations about Henke's article.

Authors:  Alberto Biete Sola; Felipe A Calvo Manuel; Bernardino Clavo Varas; Cristina Fernández Pérez; Carmen Porto Vázquez; Alejandro de la Torre Tomás; Almudena Zapatero Laborda
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

Review 7.  Treatment resistance of solid tumors: role of hypoxia and anemia.

Authors:  P Vaupel; O Thews; M Hoeckel
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

8.  Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype.

Authors:  G Kristiansen; M Rose; C Geisler; F R Fritzsche; J Gerhardt; C Lüke; A-M Ladhoff; R Knüchel; M Dietel; H Moch; Z Varga; J-P Theurillat; T A Gorr; E Dahl
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

10.  Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia.

Authors:  O Thews; T Wolloscheck; W Dillenburg; S Kraus; D K Kelleher; M A Konerding; P Vaupel
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.